drugset / Trial / NCT06575699
Rectus Sheath Block for Analgesia After Gynecological Laparotomy
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Thirty subjects undergoing laparotomy for Gynecologic oncology surgery will be prospectively enrolled and will receive a bilateral rectus sheath block (RSB) under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side. Cases will be matched in a 1:2 ratio by age, race, insurance status and duration of surgery with historical controls who received postoperative analgesia using thoracic epidural analgesia.
Timeline
- Start
- 2024-10-10
- Primary completion
- 2025-11-28
- Completion
- 2025-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 0.25 % | Other |
| Subject | Bupivacaine | Other / unclassified | 0.625 % | Other |
| Subject | Bupivacaine | Other / unclassified | 20 ml | Other |
| Subject | Bupivacaine | Other / unclassified | 133 mg | Other |
| Comparator | Hydromorphone | Other / unclassified | 10 ug/ml | Other |
Indications
No indication recorded.